Filtered By:
Cancer: Adenocarcinoma
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 24899 results found since Jan 2013.
Validity of Endoscopic Submucosal Dissection for Gastric Cancer Diagnosed as Differentiated Adenocarcinoma Before Treatment Regardless of Lesion Size
CONCLUSION: Even with a tumor diameter ≥31 mm, curative resection was achieved in about 60% of cases in which intramucosal lesions were considered possible preoperatively, but the rate was low at 8.3% for tumor diameter ≥101 mm. Long-term outcomes appear favorable, with only 0.4% of the patients dying of disease but delayed gastric emptying observed in 1.7% of cases.PMID:37681270 | DOI:10.5152/tjg.2023.22611
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Kosuke Nomura Shu Hoteya Yorinari Ochiai Takayuki Okamura Yugo Suzuki Junnosuke Hayasaka Yutaka Mitsunaga Masami Tanaka Kazuhiro Fuchinoue Hiroyuki Odagiri Satoshi Yamashita Akira Matsui Daisuke Kikuchi Source Type: research
Novel ALK immunohistochemistry assay (clone OTI1A4, Dako) is a sensitive, reliable marker for identifying ALK rearrangements in lung adenocarcinomas : A validation study
CONCLUSIONS: Immunohistochemistry-based assays provide a valid and reasonably priced alternative, especially in settings where molecular confirmatory tests are neither offered nor accessible. Given high interassay and molecular concordance, we propose that the novel Dako OTI1A4 assay can be reliably used to identify cases with ALK rearrangement.PMID:37681660 | DOI:10.1093/ajcp/aqad111
Source: American Journal of Clinical Pathology - September 8, 2023 Category: Pathology Authors: Ozgur Can Eren Cisel Aydin Mericoz Emine Bozkurtlar Pinar Bulutay Arzu Baygul Ibrahim Kulac Source Type: research
Validity of Endoscopic Submucosal Dissection for Gastric Cancer Diagnosed as Differentiated Adenocarcinoma Before Treatment Regardless of Lesion Size
CONCLUSION: Even with a tumor diameter ≥31 mm, curative resection was achieved in about 60% of cases in which intramucosal lesions were considered possible preoperatively, but the rate was low at 8.3% for tumor diameter ≥101 mm. Long-term outcomes appear favorable, with only 0.4% of the patients dying of disease but delayed gastric emptying observed in 1.7% of cases.PMID:37681270 | DOI:10.5152/tjg.2023.22611
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Kosuke Nomura Shu Hoteya Yorinari Ochiai Takayuki Okamura Yugo Suzuki Junnosuke Hayasaka Yutaka Mitsunaga Masami Tanaka Kazuhiro Fuchinoue Hiroyuki Odagiri Satoshi Yamashita Akira Matsui Daisuke Kikuchi Source Type: research
Prognostic Implication of < em > KRAS < /em > G12C Mutation in a Real-World < em > KRAS < /em > -Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
CONCLUSIONS: There was no influence of KRAS subtype (G12C versus non-G12C) on OS in patients with KRAS-mutated stage IV NSCLC treated with first-line (chemo)immunotherapy.PMID:37674812 | PMC:PMC10477684 | DOI:10.1016/j.jtocrr.2023.100543
Source: Clinical Lung Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Anneloes L Noordhof Esther M Swart Ronald A M Damhuis Lizza E L Hendriks Peter W A Kunst Mieke J Aarts Wouter H van Geffen Source Type: research
Tumoral Densities of T-Cells and Mast Cells Are Associated With Recurrence in Early-Stage Lung Adenocarcinoma
CONCLUSIONS: Analysis of the density of immune cells within the tumor and surrounding stroma reveals an association between the density of T-cells and RFS and between mast cells and RFS in early-stage LUAD. This preliminary result is a limited study with a small sample size and a lack of an independent validation set.PMID:37674811 | PMC:PMC10477685 | DOI:10.1016/j.jtocrr.2023.100504
Source: Clinical Lung Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Michael N Kammer Hidetoshi Mori Dianna J Rowe Sheau-Chiann Chen Georgii Vasiukov Thomas Atwater Maria Fernanda Senosain Sanja Antic Yong Zou Heidi Chen Tobias Peikert Steve Deppen Eric L Grogan Pierre P Massion Steve Dubinett Marc Lenburg Alexander Borows Source Type: research
Characteristics and risk factors for advanced lung cancer with pulmonary embolism: A cross-sectional, case-control study
CONCLUSION: Our study provides valuable insights into the epidemiology and prognosis of PE in lung cancer patients and suggests that a poor ECOG PS, which has not been previously reported, is an independent risk factor for PE.PMID:37675831 | DOI:10.1111/crj.13692
Source: Respiratory Care - September 7, 2023 Category: Respiratory Medicine Authors: Yongkang Huang Shiyuan Gao Ting Li Beilei Zhang Juan Du Yajuan Qian Yufei Xing Tong Zhou Minhua Shi Jian-An Huang Yixin Lian Source Type: research
Prognostic Implication of < em > KRAS < /em > G12C Mutation in a Real-World < em > KRAS < /em > -Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
CONCLUSIONS: There was no influence of KRAS subtype (G12C versus non-G12C) on OS in patients with KRAS-mutated stage IV NSCLC treated with first-line (chemo)immunotherapy.PMID:37674812 | PMC:PMC10477684 | DOI:10.1016/j.jtocrr.2023.100543
Source: Clinical Lung Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Anneloes L Noordhof Esther M Swart Ronald A M Damhuis Lizza E L Hendriks Peter W A Kunst Mieke J Aarts Wouter H van Geffen Source Type: research
Tumoral Densities of T-Cells and Mast Cells Are Associated With Recurrence in Early-Stage Lung Adenocarcinoma
CONCLUSIONS: Analysis of the density of immune cells within the tumor and surrounding stroma reveals an association between the density of T-cells and RFS and between mast cells and RFS in early-stage LUAD. This preliminary result is a limited study with a small sample size and a lack of an independent validation set.PMID:37674811 | PMC:PMC10477685 | DOI:10.1016/j.jtocrr.2023.100504
Source: Clinical Lung Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Michael N Kammer Hidetoshi Mori Dianna J Rowe Sheau-Chiann Chen Georgii Vasiukov Thomas Atwater Maria Fernanda Senosain Sanja Antic Yong Zou Heidi Chen Tobias Peikert Steve Deppen Eric L Grogan Pierre P Massion Steve Dubinett Marc Lenburg Alexander Borows Source Type: research
Cancers, Vol. 15, Pages 4467: Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in A Colorectal Cancer Model
In this study, we combined DMR with immune checkpoint inhibitors (ICIs) in a model of colon adenocarcinoma. In vitro, we observed that MR increased the expression of MHC-I and PD-L1 in both mouse and human colorectal cancer cells. We also saw an increase in the gene expression of STING, a known inducer of type I interferon signaling. Inhibition of the cGAS&ndash;STING pathway, pharmacologically or with siRNA, blunted the increase in MHC-I and PD-L1 surface and gene expression following MR. This indicated that the cGAS&ndash;STING pathway, and interferon in general, played a role in the immune response to MR...
Source: Cancers - September 7, 2023 Category: Cancer & Oncology Authors: Lauren C. Morehead Sarita Garg Katherine F. Wallis Camila C. Simoes Eric R. Siegel Alan J. Tackett Isabelle R. Miousse Tags: Article Source Type: research
